{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:24:12Z","timestamp":1785939852262,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","award":["T32DA007233"],"award-info":[{"award-number":["T32DA007233"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.dadr.2023.100178","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T19:32:27Z","timestamp":1688844747000},"page":"100178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Hepatitis C virus care cascade among people who inject drugs in Puerto Rico: Minimal HCV treatment and substantial barriers to HCV care"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1288-7684","authenticated-orcid":false,"given":"Yesenia","family":"Aponte-Mel\u00e9ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mateu-Gelabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2846-9762","authenticated-orcid":false,"given":"Benjamin","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7026-5117","authenticated-orcid":false,"given":"Chunki","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Trinidad-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Maldonado-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Agront","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dadr.2023.100178_bib0001","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12954-022-00715-4","article-title":"Substance use, injection risk behaviors, and fentanyl-related overdose risk among a sample of PWID post-Hurricane Maria","volume":"19","author":"Abadie","year":"2022","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.dadr.2023.100178_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108347","article-title":"Treatment trajectories and barriers in opioid agonist therapy for people who inject drugs in rural Puerto Rico","volume":"127","author":"Abadie","year":"2021","journal-title":"J. Subst. Abuse Treat."},{"issue":"1","key":"10.1016\/j.dadr.2023.100178_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-016-0099-9","article-title":"Understanding differences in HIV\/HCV prevalence according to differentiated risk behaviors in a sample of PWID in rural Puerto Rico","volume":"13","author":"Abadie","year":"2016","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.dadr.2023.100178_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103247","article-title":"Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: a knowledge synthesis","volume":"96","author":"Amoako","year":"2021","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.dadr.2023.100178_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108684","article-title":"Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma","volume":"137","author":"Austin","year":"2022","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.dadr.2023.100178_bib0008","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","article-title":"Strategies used by people who inject drugs to avoid stigma in healthcare settings","volume":"198","author":"Biancarelli","year":"2019","journal-title":"Drug Alcohol Depend."},{"issue":"2_suppl","key":"10.1016\/j.dadr.2023.100178_bib0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/00333549161310S214","article-title":"Improving screening methods for hepatitis C among people who inject drugs: findings from the HepTLC initiative, 2012\u20132014","volume":"131","author":"Blackburn","year":"2016","journal-title":"Public Health Rep."},{"key":"10.1016\/j.dadr.2023.100178_bib0010","article-title":"Evento hist\u00f3rico demostr\u00f3 necesidad de nuevas pol\u00edticas salubristas para pacientes con hepatitis C","author":"Burgos","year":"2021","journal-title":"Medicina Salud P\u00fablica"},{"key":"10.1016\/j.dadr.2023.100178_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/00333549221143086","article-title":"Cascade of care for hepatitis C virus infection among young adults who inject drugs in a rural county in New Mexico","author":"Carmody","year":"2023","journal-title":"Public Health Rep."},{"issue":"5","key":"10.1016\/j.dadr.2023.100178_bib0015","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cgh.2018.12.002","article-title":"Universal screening for hepatitis C: an important step in virus elimination","volume":"17","author":"Chhatwal","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.dadr.2023.100178_bib0014","unstructured":"Center for Health Law and Policy Innovation(April, 2020) Puerto Rico lifts barriers to accessing hepatitis c. https:\/\/chlpi.org\/news-and-events\/news-and-commentary\/news\/puerto-rico-lifts-barriers-to-accessing-hepatitis-c-treatment\/Diaz."},{"key":"10.1016\/j.dadr.2023.100178_bib0013","doi-asserted-by":"crossref","unstructured":"T., Col\u00f3n-L\u00f3pez, V., Alvelo-Fern\u00e1ndez, P. M., Centeno-Alvarado, N., Salas, I. Y. A., Col\u00f3n, Y. R., Mart\u00ednez, M. P., ... & Reyes-Pulliza, J. C. (2022). Prevalence and risk factors associated with hepatitis C: a cross-sectional study using data from the Puerto Rico National HIV Behavioral Surveillance System Persons Who Inject Drugs Cycle 5 2018.","DOI":"10.21203\/rs.3.rs-1803853\/v1"},{"issue":"12","key":"10.1016\/j.dadr.2023.100178_bib0017","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"9","key":"10.1016\/j.dadr.2023.100178_bib0018","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir\u2013grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"11","key":"10.1016\/j.dadr.2023.100178_bib0020","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.2105\/AJPH.2014.302114","article-title":"Addressing the HIV\/AIDS epidemic among Puerto Rican people who inject drugs: the need for a multiregion approach","volume":"104","author":"Deren","year":"2014","journal-title":"Am. J. Public Health"},{"issue":"2","key":"10.1016\/j.dadr.2023.100178_bib0021","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11524-006-9151-5","article-title":"The Puerto Rico\u2013New York airbridge for drug users: description and relationship to HIV risk behaviors","volume":"84","author":"Deren","year":"2007","journal-title":"J. Urban Health"},{"issue":"Supplement_5","key":"10.1016\/j.dadr.2023.100178_bib0022","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1086\/427441","article-title":"Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users","volume":"40","author":"Edlin","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.dadr.2023.100178_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135645","article-title":"Drug authorization for sofosbuvir\/ledipasvir (Harvoni) for chronic HCV infection in a real-world cohort: a new barrier in the HCV care cascade","volume":"10","author":"Do","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.dadr.2023.100178_bib0025","unstructured":"El Punto en la Monta\u00f1a. Puerto Rico Consciente. Retrieved from https:\/\/www.elpuntopr.org\/coalicion-nacional-vhc."},{"key":"10.1016\/j.dadr.2023.100178_bib0026","unstructured":"First Medical Health Plan. (2020). Carta Tr\u00e1mite. Retrieved from https:\/\/www.firstmedicalvital.com\/wp-content\/uploads\/2021\/01\/Comunicado-referente-a-la-Carta-Normativa-20-1210-relacionada-al-Proceso-de-Inclusi\u00f3n-de-M\u00e9dicos-Primarios-Certificados-como-Prescriptores-de-Hepatitis-C.pdf."},{"key":"10.1016\/j.dadr.2023.100178_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.103057","article-title":"The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: major gaps for migrants","volume":"90","author":"Folch","year":"2021","journal-title":"Int. J. Drug Policy"},{"issue":"1","key":"10.1016\/j.dadr.2023.100178_bib0028","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J. Translat. Intern. Med."},{"issue":"2","key":"10.1016\/j.dadr.2023.100178_bib0029","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2105\/AJPH.2019.305487","article-title":"Puerto Rican syndemics: opiates, overdoses, HIV, and the hepatitis C virus in a context of ongoing crises","volume":"110","author":"Gelp\u00ed-Acosta","year":"2020","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.dadr.2023.100178_bib0030","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.drugpo.2019.03.016","article-title":"Injection risk norms and practices among migrant Puerto Rican people who inject drugs in New York City: the limits of acculturation theory","volume":"69","author":"Gelp\u00ed-Acosta","year":"2019","journal-title":"Int. J. Drug Policy"},{"issue":"12","key":"10.1016\/j.dadr.2023.100178_bib0031","first-page":"720","article-title":"Hepatitis C virus detection and treatment in rural communities","volume":"14","author":"Gordon","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"issue":"suppl_1","key":"10.1016\/j.dadr.2023.100178_bib0032","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/infdis\/jis928","article-title":"Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV\/HIV coinfection: action required at the system, provider, and patient levels","volume":"207","author":"Grebely","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.dadr.2023.100178_bib0033","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.dadr.2023.100178_bib0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugpo.2017.08.001","article-title":"Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy","volume":"47","author":"Grebely","year":"2017","journal-title":"Int. J. Drug Policy"},{"issue":"1","key":"10.1016\/j.dadr.2023.100178_bib0035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2105\/AJPH.91.1.42","article-title":"Sharing of drug preparation equipment as a risk factor for hepatitis C","volume":"91","author":"Hagan","year":"2001","journal-title":"Am. J. Public Health"},{"issue":"1","key":"10.1016\/j.dadr.2023.100178_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7517-10-7","article-title":"Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors","volume":"10","author":"Harris","year":"2013","journal-title":"Harm Reduct. J."},{"issue":"4","key":"10.1016\/j.dadr.2023.100178_bib0037","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1307","article-title":"Effectiveness of ledipasvir\/sofosbuvir and sofosbuvir\/velpatasvir in people who inject drugs and\/or those in opioid agonist therapy","volume":"3","author":"Janjua","year":"2019","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.dadr.2023.100178_bib0038","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drugpo.2017.05.022","article-title":"Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia","volume":"47","author":"Iversen","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.dadr.2023.100178_bib0039","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fpubh.2017.00348","article-title":"Patterns and gaps identified in a systematic review of the hepatitis C virus care continuum in studies among people who use drugs","volume":"5","author":"Jordan","year":"2017","journal-title":"Front. Public Health"},{"issue":"2","key":"10.1016\/j.dadr.2023.100178_bib0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/jvh.13437","article-title":"Hepatitis C testing and treatment uptake among young people who use opioids in New York City: A cross-sectional study","volume":"28","author":"Kapadia","year":"2021","journal-title":"J. Viral Hepat."},{"issue":"20","key":"10.1016\/j.dadr.2023.100178_bib0041","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.dadr.2023.100178_bib0043","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2019.02.018","article-title":"Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy","volume":"71","author":"Mac\u00edas","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.dadr.2023.100178_bib0045","doi-asserted-by":"crossref","unstructured":"Morris, M. D., Mirzazadeh, A., Evans, J. L., Briceno, A., Coffin, P., Hahn, J. A., & Page, K. A. (2019). Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: low number treated. Drug Alcoh. Depend., 198, 133-135.","DOI":"10.1016\/j.drugalcdep.2019.02.008"},{"issue":"1","key":"10.1016\/j.dadr.2023.100178_bib0046","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1521\/aeap.2006.18.1.81","article-title":"Social support and HIV\u2013related injection risk among puerto rican migrant and nonmigrant injection drug users recruited in New York city","volume":"18","author":"Mino","year":"2006","journal-title":"AIDS Educ. Prevent."},{"key":"10.1016\/j.dadr.2023.100178_bib0048","unstructured":"National Hepatitis Viral Roundtable (2023). Hepatitis C state of medicaid access report card: Puerto Rico. Retrieved from https:\/\/stateofhepc.org\/wp-content\/uploads\/2021\/05\/Puerto-Rico-February-2023.pdf."},{"issue":"4","key":"10.1016\/j.dadr.2023.100178_bib0051","article-title":"Hepatitis C in Puerto Rico: a time for public health action","volume":"26","author":"P\u00e9rez","year":"2007","journal-title":"P R. Health Sci. J."},{"issue":"2","key":"10.1016\/j.dadr.2023.100178_bib0052","article-title":"Tackling the health challenge posed by hepatitis C in Puerto Rico: a call for immediate public health actions","volume":"34","author":"P\u00e9rez","year":"2015","journal-title":"P R. Health Sci. J."},{"issue":"11","key":"10.1016\/j.dadr.2023.100178_bib0053","first-page":"10","article-title":"Protocol: Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: Drug use & Infections in Vietnam\u2013hepatitis C)","author":"Rapoud","year":"2020","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.dadr.2023.100178_bib0054","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cgh.2016.03.040","article-title":"Disparities in absolute denial of modern hepatitis C therapy by type of insurance","volume":"14","author":"Re","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.dadr.2023.100178_bib0055","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11524-006-9109-7","article-title":"Prevalence and correlates of hepatitis C virus infection among street-recruited injection drug users in San Juan, Puerto Rico","volume":"83","author":"Reyes","year":"2006","journal-title":"J. Urban Health"},{"issue":"4","key":"10.1016\/j.dadr.2023.100178_bib0056","first-page":"369","article-title":"Mortality among hispanic drug users in Puerto Rico","volume":"22","author":"Robles","year":"2003","journal-title":"P R. Health Sci. J."},{"issue":"7","key":"10.1016\/j.dadr.2023.100178_bib0057","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/cid\/ciaa105","article-title":"Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs","volume":"71","author":"Rosenthal","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.dadr.2023.100178_bib0058","first-page":"2020","article-title":"Reported low uptake of HCV testing among people who inject drugs in urban Vietnam","author":"Thinh","year":"2020","journal-title":"Biomed. Res. Int."},{"issue":"21","key":"10.1016\/j.dadr.2023.100178_bib0059","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global elimination of chronic hepatitis","volume":"380","author":"Thomas","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.dadr.2023.100178_bib0060","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drugalcdep.2018.11.026","article-title":"Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle","volume":"195","author":"Tsui","year":"2019","journal-title":"Drug Alcoh. Depend."},{"issue":"7","key":"10.1016\/j.dadr.2023.100178_bib0061","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101554","article-title":"The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis","volume":"9","author":"Yehia","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.dadr.2023.100178_bib0062","unstructured":"Univisi\u00f3n Puerto Rico. Prevalencia de hepatitis C en la Isla es la m\u00e1s alta de EEUU, pero llegar al tratamiento es un v\u00eda crucis. Retrieved from https:\/\/www.univision.com\/local\/puerto-rico-wlii\/prevalencia-hepatitis-c-puerto-rico-alta-eeuu#."},{"key":"10.1016\/j.dadr.2023.100178_bib0064","series-title":"Progress Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers in Low-and Middle-Income Countries","year":"2018"},{"key":"10.1016\/j.dadr.2023.100178_bib0065","series-title":"Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief (No. WHO\/HIV\/2016.04)","year":"2016"},{"issue":"10","key":"10.1016\/j.dadr.2023.100178_bib0066","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3109\/10826081003682842","article-title":"Needle sharing among Puerto Rican injection drug users in Puerto Rico and Massachusetts: place of birth and residence matter","volume":"45","author":"Zerden","year":"2010","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.dadr.2023.100178_bib0063","unstructured":"World Health Organization.(2022). Hepatitis C. Retrieved from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c#:~:text=DAAs%20can%20cure%20most%20persons,pangenotypic%20treatments%20used%20for%20adults."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724623000483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724623000483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:33:40Z","timestamp":1757421220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724623000483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":55,"alternative-id":["S2772724623000483"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2023.100178","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C virus care cascade among people who inject drugs in Puerto Rico: Minimal HCV treatment and substantial barriers to HCV care","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2023.100178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100178"}}